Clinuvel Pharmaceuticals
CUV.AX
#7299
Rank
A$0.57 B
Marketcap
$11.56
Share price
-0.34%
Change (1 day)
-13.30%
Change (1 year)

P/E ratio for Clinuvel Pharmaceuticals (CUV.AX)

P/E ratio at the end of 2023: 27.7

According to Clinuvel Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 17.7666. At the end of 2023 the company had a P/E ratio of 27.7.

P/E ratio history for Clinuvel Pharmaceuticals from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202327.7-15.09%
202232.6-33.79%
202149.2-26.37%
202066.9-15.19%
201978.9132.79%
201833.9-6.85%
201736.4-170.91%
2016-51.3407.36%
2015-10.126.9%
2014-7.9622.36%
2013-6.51111.35%
2012-3.0814.11%
2011-2.70-39.21%
2010-4.447.17%
2009-4.14-12.47%
2008-4.73-74.45%
2007-18.5329.82%
2006-4.3131.07%
2005-3.29-73.58%
2004-12.4124.44%
2003-5.5461.46%
2002-3.43-4.37%
2001-3.59

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.